Abdominal obesity: The cholesterol of the 21st century?

Canadian Journal of Cardiology

Volumn 24, Issue SUPPL.D, 2008, Pages 7D-12D

  Després, Jean Pierre ^a,b   Arsenault, Benoit J ^a,c   Côté, Mélanie ^a,c   Cartier, Amélie ^a,c   Lemieux, Isabelle ^a  

^a LAVAL UNIVERSITY   (Canada)

^b Division of Kinesiology   (Canada)

^c UNIVERSITÉ LAVAL   (Canada)

Author keywords

Abdominal obesity; Cardiometabolic risk; Cardiovascular disease; Ectopic fat; Type 2 diabetes; Waist circumference

Indexed keywords

CHOLESTEROL;

ABDOMINAL FAT; BLOOD; CARDIOVASCULAR DISEASE; HEALTH; HUMAN; MORBIDITY; OBESITY; REVIEW; RISK FACTOR;

ABDOMINAL FAT; CARDIOVASCULAR DISEASES; CHOLESTEROL; HUMANS; MORBIDITY; OBESITY; RISK FACTORS; WORLD HEALTH;

EID: 55949118484     PISSN: 0828282X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0828-282X(08)71043-2     Document Type: Conference Paper

References (62)

1. Kannel WB, Dawber TR, Friedman GD, Glennon WE, McNamara PM. Risk factors in coronary heart disease. An evaluation of several serum lipids as predictors of coronary heart disease; The Framingham Study. Ann Intern Med 1964;61:888-99.
2. Cullen P, Schulte H, Assmann G. Smoking, lipoproteins and coronary heart disease risk. Data from the Munster Heart Study (PROCAM). Eur Heart J 1998;19:1632-41.
3. Lamarche B, Moorjani S, Lupien PJ, et al. Apolipoprotein A-I and B levels and the risk of ischemic heart disease during a five-year follow-up of men in the Québec cardiovascular study. Circulation 1996;94:273-8.
4. Yusuf S, Hawken S, Ounpuu S, et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): Case-control study. Lancet 2004;364:937-52.
5. Stamler J, Wentworth D, Neaton JD. Is the relationship between serum cholesterol and risk of premature death from coronary heart disease continuous and graded? Findings in 356,222 primary screenees of the Multiple Risk Factor Intervention Trial (MRFIT). JAMA 1986;256:2823-8.
6. Greenland P, Knoll MD, Stamler J, et al. Major risk factors as antecedents of fatal and nonfatal coronary heart disease events. JAMA 2003;290:891-7.
7. Khot UN, Khot MB, Bajzer CT, et al. Prevalence of conventional risk factors in patients with coronary heart disease. JAMA 2003;290:898-904.
8. Reid RD, Quinlan B, Riley DL, Pipe AL. Smoking cessation: Lessons learned from clinical trial evidence. Curr Opin Cardiol 2007;22:280-5.
9. Onysko J, Maxwell C, Eliasziw M, et al. Large increases in hypertension diagnosis and treatment in Canada after a healthcare professional education program. Hypertension 2006;48:853-60.
10. Baigent C, Keech A, Kearney PM, et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 2005;366:1267-78.
11. Kearney PM, Blackwell L, Collins R, et al. Efficacy of cholesterollowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: A meta-analysis. Lancet 2008;371:117-25.
12. Reid RD, Pipe AL, Quinlan B. Promoting smoking cessation during hospitalization for coronary artery disease. Can J Cardiol 2006;22:775-80.
13. Manuel DG, Leung M, Nguyen K, Tanuseputro P, Johansen H. Burden of cardiovascular disease in Canada. Can J Cardiol 2003;19:997-1004.
14. Ford ES, Capewell S. Coronary heart disease mortality among young adults in the U.S. from 1980 through 2002: Concealed leveling of mortality rates. J Am Coll Cardiol 2007;50:2128-32.
15. Ford ES, Ajani UA, Croft JB, et al. Explaining the decrease in U.S. deaths from coronary disease, 1980-2000. N Engl J Med 2007;356:2388-98.
16. Katzmarzyk PT. The Canadian obesity epidemic, 1985-1998. CMAJ 2002;166:1039-40.
17. Ford ES, Mokdad AH, Giles WH. Trends in waist circumference among U.S. adults. Obes Res 2003;11:1223-31.
18. Wang Y, Mi J, Shan XY, Wang QJ, Ge KY. Is China facing an obesity epidemic and the consequences? The trends in obesity and chronic disease in China. Int J Obes (Lond) 2007;31:177-88.
19. Li S, Chen W, Srinivasan SR, et al. Childhood cardiovascular risk factors and carotid vascular changes in adulthood: The Bogalusa Heart Study. JAMA 2003;290:2271-6.
20. Drapeau V, Lemieux I, Richard D, et al. Metabolic profile in severely obese women is less deteriorated than expected when compared to moderately obese women. Obes Surg 2006;16:501-9.
21. Lemieux I, Drapeau V, Richard D, et al. Waist girth does not predict metabolic complications in severely obese men. Diabetes Care 2006;29:1417-9.
22. Després JP, Moorjani S, Lupien PJ, et al. Regional distribution of body fat, plasma lipoproteins, and cardiovascular disease. Arteriosclerosis 1990;10:497-511.
23. Pouliot MC, Després JP, Nadeau A, et al. Visceral obesity in men. Associations with glucose tolerance, plasma insulin, and lipoprotein levels. Diabetes 1992;41:826-34.
24. Vague J. Sexual differentiation, a factor affecting the forms of obesity. Presse Méd 1947;30:339-40.
25. Vague J. The degree of masculine differentiation of obesities: A factor determining predisposition to diabetes, atherosclerosis, gout and ulric calculous disease. Am J Clin Nutr 1956;4:20-34.
26. Albrink MJ, Meigs JW. Interrelationship between skinfold thickness, serum lipids and blood sugar in normal men. Am J Clin Nutr 1964;15:255-61.
27. Allard C, Goulet C. Serum lipids: An epidemiological study of an active Montreal population. Can Med Assoc J 1968;98:627-37.
28. Kissebah AH, Vydelingum N, Murray R, et al. Relation of body fat distribution to metabolic complications of obesity. J Clin Endocrinol Metab 1982;54:254-60.
29. Lapidus L, Bengtsson C, Larsson B, et al. Distribution of adipose tissue and risk of cardiovascular disease and death: A 12 year follow up of participants in the population study of women in Gothenberg, Sweden. Br Med J 1984;289:1257-61.
30. Larsson B, Svardsudd K, Welin L, et al. Abdominal adipose tissue distribution, obesity, and risk of cardiovascular disease and death: 13 year follow-up of participants in the study of men born in 1913. Br Med J 1984;288:1401-4.
31. Ohlson LO, Larsson B, Svardsudd K, et al. The influence of body fat distribution on the incidence of diabetes mellitus: 13.5 years of follow-up of the participants in the study of men born in 1913. Diabetes 1985;34:1055-8.
32. Balkau B, Deanfield JE, Després JP, et al. International Day for the Evaluation of Abdominal Obesity (IDEA): A study of waist circumference, cardiovascular disease, and diabetes mellitus in 168,000 primary care patients in 63 countries. Circulation 2007;116:1942-51.
33. Canoy D, Boekholdt SM, Wareham N, et al. Body fat distribution and risk of coronary heart disease in men and women in the European Prospective Investigation Into Cancer and Nutrition in Norfolk cohort: a population-based prospective study. Circulation 2007;116:2933-43.
34. Rexrode KM, Carey VJ, Hennekens CH, et al. Abdominal adiposity and coronary heart disease in women. JAMA 1998;280:1843-8.
35. Lakka HM, Lakka TA, Tuomilehto J, Salonen JT. Abdominal obesity is associated with increased risk of acute coronary events in men. Eur Heart J 2002;23:706-13.
36. Yusuf S, Hawken S, Ounpuu S, et al. Obesity and the risk of myocardial infarction in 27,000 participants from 52 countries: A case-control study. Lancet 2005;366:1640-9.
37. Després JP, Lemieux I, Prud'homme D. Treatment of obesity: Need to focus on high risk abdominally obese patients. BMJ 2001;322:716-20.
38. Brunzell JD, Fujimoto WY. Body fat distribution and dyslipidemia. Am J Med 1995;99:457-8.
39. Després JP, Nadeau A, Tremblay A, et al. Role of deep abdominal fat in the association between regional adipose tissue distribution and glucose tolerance in obese women. Diabetes 1989;38:304-9.
40. Juhan-Vague I, Alessi MC. PAI-1, obesity, insulin resistance and risk of cardiovascular events. Thromb Haemost 1997;78:656-60.
41. Lemieux I, Pascot A, Prud'homme D, et al. Elevated C-reactive protein: Another component of the atherothrombotic profile of abdominal obesity. Arterioscler Thromb Vasc Biol 2001;21:961-7.
42. Ross R, Aru J, Freeman J, Hudson R, Janssen I. Abdominal adiposity and insulin resistance in obese men. Am J Physiol Endocrinol Metab 2002;282:E657-63.
43. Ross R, Freeman J, Hudson R, Janssen I. Abdominal obesity, muscle composition, and insulin resistance in premenopausal women. J Clin Endocrinol Metab 2002;87:5044-51.
44. Hotamisligil GS. Molecular mechanisms of insulin resistance and the role of the adipocyte. Int J Obes Relat Metab Disord 2000;24(Suppl 4):S23-7.
45. Flier JS. The adipocyte: Storage depot or node on the energy information superhighway? Cell 1995;80:15-8.
46. Després JP, Lemieux I. Abdominal obesity and metabolic syndrome. Nature 2006;444:881-7.
47. Pouliot MC, Després JP, Moorjani S, et al. Regional variation in adipose tissue LPL activity: Association with plasma high density lipoproteins levels. Eur J Clin Invest 1991;21:398-405.
48. Lemieux I, Poirier P, Bergeron J, et al. Hypertriglyceridemic waist: A useful screening phenotype in preventive cardiology? Can J Cardiol 2007;23:23B-31B.
49. Fuller JH, Shipley MJ, Rose G, Jarrett RJ, Keen H. Mortality from coronary heart disease and stroke in relation to degree of glycaemia: The Whitehall study. Br Med J (Clin Res Ed) 1983;287:867-70.
50. Kannel WB, McGee DL. Diabetes and cardiovascular disease. The Framingham study. JAMA 1979;241:2035-8.
51. Stamler J, Vaccaro O, Neaton JD, Wentworth D. Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care 1993;16:434-44.
52. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998;352:837-53.
53. Nathan DM, Cleary PA, Backlund JY, et al. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med 2005;353:2643-53.
54. Blackburn P, Lemieux I, Lamarche B, et al. Type 2 diabetes without the atherogenic metabolic triad does not predict angiographically assessed coronary artery disease in women. Diabetes Care 2008;31:170-2.
55. Gaede P, Vedel P, Larsen N, Jensen GV, Parving HH, Pedersen O. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 2003;348:383-93.
56. Alexander CM, Landsman PB, Teutsch SM, Haffner SM. NCEPdefined metabolic syndrome, diabetes, and prevalence of coronary heart disease among NHANES III participants age 50 years and older. Diabetes 2003;52:1210-4.
57. Pi-Sunyer X, Blackburn G, Brancati FL, et al. Reduction in weight and cardiovascular disease risk factors in individuals with type 2 diabetes: One-year results of the Look AHEAD trial. Diabetes Care 2007;30:1374-83.
58. Church TS, LaMonte MJ, Barlow CE, Blair SN. Cardiorespiratory fitness and body mass index as predictors of cardiovascular disease mortality among men with diabetes. Arch Intern Med 2005;165:2114-20.
59. Galassi A, Reynolds K, He J. Metabolic syndrome and risk of cardiovascular disease: A meta-analysis. Am J Med 2006;119:812-9.
60. Gami AS, Witt BJ, Howard DE, et al. Metabolic syndrome and risk of incident cardiovascular events and death: a systematic review and meta-analysis of longitudinal studies. J Am Coll Cardiol 2007;49:403-14.
61. Knowler WC, Barrett-Connor E, Fowler SE, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002;346:393-403.
62. Tuomilehto J, Lindstrom J, Eriksson JG, et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 2001;344:1343-50.